MA-RENAGADE-THERAPEUTICS
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Joe Bolen, Ph.D., an Executive Partner at MPM BioImpact, former Chief Scientific Officer at PureTech Health and former President of Research and Development of Moderna Therapeutics, will serve as the company’s first Chief Science Innovation Officer.
“Joe is a pioneering scientist and drug development expert who brings to ReNAgade more than four decades of experience in oncology and immunology,” said Amit D. Munshi, Chief Executive Officer of ReNAgade. “In this newly created position, Joe will advise the company on research strategy and direction as well as help drive our lead programs towards development milestones. We are very excited to welcome him to the team.”
“ReNAgade is leading the industry in its efforts to transcend the boundaries of RNA medicine,” said Dr. Bolen. “I am thrilled to join the company and undertake an important role in shaping research plans as we work together to translate ReNAgade’s multi-modal RNA platform into therapeutic advances for patients with high unmet medical needs.”
Dr. Bolen brings more than 45 years of industry and research experience to ReNAgade. He is an Executive Partner at MPM BioImpact and was formerly Chief Scientific Officer at PureTech Health. Before joining PureTech, he oversaw all aspects of research and development for Moderna Therapeutics as President of Research & Development and Chief Scientific Officer. Previously, he was Chief Scientific Officer at Millennium Pharmaceuticals and Global Head of Oncology Research at Takeda Pharmaceutical Company. Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough (DNAX) and Bristol Myers Squibb. He began his career at the National Institutes of Health (NIH), where he contributed to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. Joe earned a Ph.D. in Immunology and conducted his postdoctoral training in molecular virology at Kansas State University Cancer Center. He graduated from the University of Nebraska with a B.S. in Microbiology and Chemistry.
About ReNAgade Therapeutics
ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.
To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.
ReNAgade Therapeutics—RNA Without Limits
For more information about the company, its technologies, and its leadership, visit https://renagadetx.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227482038/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ITA Group Expands Global Event Capabilities With Two European Acquisitions9.12.2025 16:00:00 CET | Press release
Engagement solutions leader acquires C2events in England and Daymakers in the Netherlands, strengthening their ability to deliver locally managed experiences worldwide ITA Group, a global leader in engagement solutions, is announcing the strategic acquisition of two award-winning European event agencies: C2events, based in West Yorkshire, England, and Daymakers, based in Utrecht, Netherlands. Effective October 31, 2025, these acquisitions significantly expand ITA Group's local presence and event capabilities throughout Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209885574/en/ Back row: Mark Saxby – C2, Executive Director, Brent Vander Waal – ITA Group, CEO; Front row: Sarah Haines – ITA Group, President Event Solutions, Sophie Hopes – C2, Client Services Director, Danielle Gunn – C2, Client Services Director, Cheryl Clarke – C2, Executive Director, Erica Lalk – ITA Group, Director - Global & Event Strategy The
Grid Dynamics Signs Strategic Collaboration Agreement with AWS to Advance Data Foundations for Generative AI9.12.2025 15:15:00 CET | Press release
Key Takeaways: Grid Dynamics has signed a multi-year agreement with Amazon Web Services (AWS) to accelerate AI-related services for enterprise customers. The agreement extends a 15-year collaboration and provides Grid Dynamics access to the AWS Data Foundations for Generative AI Program designed to help enterprises adopt and scale AI-enabled solutions. Through this expanded collaboration, Grid Dynamics is set to empower clients across every stage of their AI journey with modern, scalable, and secure data foundations from AWS. Grid Dynamics Holdings, Inc. (NASDAQ: GDYN) (Grid Dynamics), a premier IT consulting and digital services provider, today announced it has entered into a multi-year strategic collaboration agreement (SCA) with Amazon Web Services (AWS). The agreement focuses on enabling and scaling generative AI journeys for enterprise companies, extending a 15-year relationship between the companies. The collaboration provides Grid Dynamics access to the AWS Data Foundations for
Indero Named Best Employer by Mercer9.12.2025 15:00:00 CET | Press release
Indero, a global CRO specializing in dermatology and rheumatology, has been honored by Mercer, recognizing its excellence as a Best Employer. Indero is proud of its long-term commitment to building a workplace culture defined by trust, fairness, and meaningful employee experiences and believes this distinction reflects its positive impact in 2025. The Best Employers in Canada – Powered by Mercer certification program recognizes organizations that consistently deliver a positive and engaging employee experience, based on employee feedback. The degree of employee engagement is a crucial factor for both current and prospective clients and partners, since motivated and committed employees are more likely to excel in their roles and ensure the highest standards in the organization’s products and services. Formerly known as the Kincentric Best Employers, the program has highlighted Canada’s top workplaces for over 25 years and now benefits from Mercer’s expanded global reach and one of the m
Gulf Oil Selects DataXstream’s OMS+ Portal to Power LATAM Digital Transformation9.12.2025 14:33:00 CET | Press release
New deployment will enable Gulf Oil to modernize the distributor experience, support long-term digital growth and deliver a unified customer experience on SAP S/4HANA DataXstream LLC, an SAP® Endorsed App partner developing innovative solutions for SAP sales and distribution, today announced that Gulf Oil, a globally recognized lubricant company with operations in more than 25 countries, has selected OMS+ Portal to modernize and unify the company’s customer-facing sales platform across Latin America. The project is part of a broader initiative to streamline operations, enhance scalability and deliver a seamless buying experience that is fully integrated with SAP S/4HANA. As Gulf Oil continues its footprint across LATAM, the company needed a solution that would not only elevate the customer experience, but also provide the flexibility and performance needed to scale. OMS+ Portal will serve as the central platform for Gulf’s distributor network, offering a unified, SAP-embedded environme
Guardant Health and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy9.12.2025 14:05:00 CET | Press release
Leading European Hospital System Begins Offering On-site Liquid Biopsy Testing Based on Proprietary Guardant360® CDx Technology Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the successful launch of FPG 360, an in-house liquid biopsy testing service at the Fondazione Policlinico Universitario Agostino Gemelli IRCCS (Policlinico Gemelli) in Rome, Italy. This partnership is the latest in a series of public-private partnerships Guardant Health has formed with top-tier European academic and research hospitals that embed its groundbreaking technology with existing care pathways to expand access to more cancer patients. Policlinico Gemelli will offer on-site liquid biopsy testing based on Guardant360® CDx technology. The collaboration expands access to precision oncology diagnostics and supports both routine care and clinical research. FPG 360 is one of the first dedicated liquid biopsy testing facilities in Italy housed within a hospital system. P
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom